The company said its product sales for fiscal 2023 from its COVID-COVID-19 vaccine were approximately $6.7 billion (unaudited), including approximately $0.6 billion of deferred revenue recognized related to its efforts with GAVI. It said the figures are preliminary and could change while the audit is ongoing.

1. 01

   The company said its product sales for fiscal 2023 from its COVID-COVID-19 vaccine were approximately $6.7 billion (unaudited), including approximately $0.6 billion of deferred revenue recognized related to its efforts with GAVI. It said the figures are preliminary and could change while the audit is ongoing.

2. 02

   The company said cash, cash equivalents and marketable securities investments as of December 31, 2023 (unaudited) were in excess of $13 billion. It said full financial details will be reported on its earnings call on February 22, 2024.

3. 03

   The company continues to expect product sales of approximately $4 billion in 2024, mostly in the second half of the year, primarily from COVID-COVID-19 vaccine sales and the launch of its RSV vaccine. It said it expects a return to sales growth in 2025 and break-even in 2026.

4. 04

   The company said it has filed for regulatory approval of its RSV vaccine (mRNA-1345) for adults 60 years or older and expects approvals to begin in the first half of 2024. As of January 2024, it said 9 of its 45 programs are in late-stage development.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.